Aaron S. Mansfield, M.D., is a medical oncologist at Mayo Clinic with a focus on thoracic malignancies and early therapeutics. He is co-director of the Precision Cancer Therapeutics Program within the Mayo Clinic Center for Individualized Medicine.
He has played a significant role, including principal investigator, in clinical trials leading to Food and Drug Administration approval of agents for thoracic malignancies. These include atezolizumab for small cell lung cancer, pralsetinib for rearranged during transfection (RET) fusion-positive non-small cell lung cancer, and the combination of ipilimumab and nivolumab for mesothelioma.
His laboratory runs many translational projects to discover and validate biomarkers in thoracic malignancies. Further, Dr. Mansfield has received funding from multiple peer-reviewed organizations, including the National Cancer Institute, the Department of Defense and the Mark Foundation for Cancer Research.
- Immunotherapy biomarkers. Dr. Mansfield and his colleagues have identified a signature that predicts which patients with mesothelioma are most likely to benefit from treatment with immunotherapy. This signature is being studied in other tumor types. Dr. Mansfield is also working on developing blood-based biomarkers.
- Drug development. Dr. Mansfield is the principal investigator of multiple cooperative group clinical trials including the ROS1-crizotinib arm of the National Cancer Institute-sponsored Molecular Analysis for Therapy Choice (NCI-MATCH) clinical trial and others for pleural and peritoneal mesothelioma. He collaborates with many pharmaceutical companies to offer new therapies to patients.
Significance to patient care
Dr. Mansfield hopes to introduce new treatments for lung cancer, mesothelioma and rare tumors. He is a principal investigator on many clinical trials that are available to patients to participate in.
- Co-director, Precision Cancer Therapeutics Program, Mayo Clinic Center for Individualized Medicine, 2020-present
- Provider Recognition Award, Mayo Clinic Experience, 2020
- Journal of Thoracic Oncology
- Top reviewer, 2016-present
- Letter of recognition for reviewing 22 manuscripts, 2016
- American Society of Clinical Oncology (ASCO) travel award, 2013
- Tow Shung Tan Humanism in Medicine Award, 2013
- ASCO Merit Award, 2012